Hugh S. Griffith, NuCana’s Founder and Chief Executive Officer, said: “We are delighted to have been able to showcase these data. For the first time, we have presented data from our lead program of NUC-3373 in second-line colorectal cancer from the NuTide:302 study, which has shown encouraging signs of efficacy and continues to demonstrate a favorable safety profile. Four out of seven patients who received fluoropyrimidine plus oxaliplatin-based therapy as a first-line treatment achieved a longer PFS on NUFIRI-bev in the second-line setting where PFS is typically five months shorter. This result gives us further confidence in our ongoing randomized Phase 2 NuTide:323 study.”
